|Cathepsin S inhibitorBlocks MHCII antigen presentation|
Sample solution is provided at 25 µL, 10mM.
Related Compound Libraries
|A slow, tight-binding reversible inhibitor of recombinant cathepsin S (Ki = 185 pM). Exhibits about 410-fold greater selectivity for cathepsin S compared to cathepsin B (Ki = 76 nM).|
|Cas No.||1373215-15-6||SDF||Download SDF|
|Chemical Name||[(3R,4S)-4-[(4-fluorobenzoyl)amino]-6-[4-(oxetan-3-yl)piperazin-1-yl]-3,4-dihydro-2H-chromen-3-yl] N-methylcarbamate|
|Solubility||>24.3mg/mL in DMSO||Storage||Store at -20°C|
Ki: 0.185 nM
Cathepsin S is a lysosomal cysteine protease, playing an important role in antigen presentation. The inhibition of Cathepsin S is expected to result in immunosuppression, which makes this enzyme an attractive target to potentially treat autoimmune and inflammatory diseases. Cathepsin S inhibitor is a novel Cathepsin S inhibitor.
In vitro: Cathepsin S inhibitor was a slow, tight-binding reversible inhibitor of recombinant cathepsin S, exhibiting greater selectivity for cathepsin S compared to cathepsin B .
In vivo: No animal in vivo data available currently
Clinical trial: Oral Cathepsin S inhibitor that blocked MHCII antigen presentation could result in a T-cell-selective immunosuppressant agent with improved safety over the current standard of care for the treatment of rheumatoid arthritis, psoriasis, multiple sclerosis and other autoimmune-based inflammatory diseases .
 Wiener JJ, Sun S, Thurmond RL. Recent advances in the design of cathepsin S inhibitors. Curr Top Med Chem. 2010;10(7):717-32.
 Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004-2010. Expert Opin Ther Pat. 2011;21(3):311-37.